株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

網膜芽細胞腫:パイプライン製品の分析

Retinoblastoma - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192809
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
網膜芽細胞腫:パイプライン製品の分析 Retinoblastoma - Pipeline Review, H2 2017
出版日: 2017年10月31日 ページ情報: 英文 55 Pages
概要

網膜芽細胞腫は網膜から発生する眼癌です。症候は、白色瞳孔、目の赤み、視覚障害、虹彩の色が異なる、眼球腫脹などです。素因は、年齢や遺伝です。治療は化学療法、放射線治療、手術などを行います。

当レポートでは、世界各国での網膜芽細胞腫治療法のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

網膜芽細胞腫;概要

治療薬の開発

  • パイプライン製品の概要
  • 企業で開発されたパイプライン
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Cellceutix Corp
  • Icon Bioscience Inc
  • PepVax Inc
  • Recombio SL

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9833IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoblastoma - Overview
    • Retinoblastoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Retinoblastoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinoblastoma - Companies Involved in Therapeutics Development
    • Icon Bioscience Inc
    • Innovation Pharmaceuticals Inc
    • Ophthotech Corp
    • PepVax Inc
    • Recombio SL
    • VCN Biosciences SL
  • Retinoblastoma - Drug Profiles
    • FL-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melphalan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nutlin-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegpleranib sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PVX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • racotumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
    • Featured News & Press Releases
      • Jul 26, 2017: Ophthotech Announces Update on Fovista
      • Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
      • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
      • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
      • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
      • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
      • Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Retinoblastoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Retinoblastoma - Pipeline by Icon Bioscience Inc, H2 2017
  • Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
  • Retinoblastoma - Pipeline by Ophthotech Corp, H2 2017
  • Retinoblastoma - Pipeline by PepVax Inc, H2 2017
  • Retinoblastoma - Pipeline by Recombio SL, H2 2017
  • Retinoblastoma - Pipeline by VCN Biosciences SL, H2 2017
  • Retinoblastoma - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Retinoblastoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top